US DTRA to fund preclinical work on Evolva's antibiotic GC-072
SIX: EVE) today announces it has entered into a contract (HDTRA1-14-C-0122) with the US Defense Threat Reduction Agency…
SIX: EVE) today announces it has entered into a contract (HDTRA1-14-C-0122) with the US Defense Threat Reduction Agency…
Evolva Holding SA (SIX: EVE, «Evolva» oder die «Gesellschaft») meldet, dass Credit Suisse, die die am 25. Februar 2014 a…
Evolva Holding SA (SIX: EVE) presented extensive preclinical data on EV-035 at ICAAC, the world's premier international…
Die Evolva Holding AG (SIX: EVE) gab heute die Top-Line-Ergebnisse für die ersten 32 Patienten bekannt, die in die Phase…
Evolva Holding SA (SIX: EVE) announced today that it has received regulatory clearance to progress its pharmaceutical co…
Evolva Holding AG (SIX: EVE), die mittels synthetischer Biologie neuartige Medikamente und Lebensmittelzutaten entwickel…
Evolva Holding SA (SIX: EVE) has today published the agenda items for the Annual General Meeting, to be held on 18 May 2…
Evolva Holding SA (SIX: EVE) announced today that it has signed an agreement with San Francisco, California-based Abunda…
Evolva Holding SA (SIX: EVE) today announced that Dr. Melya Hughes Crameri, CEO of Evolva's US subsidiary Genetic Chemis…